Comparison between the effect of two regimens for hepatitis c treatment [qurevo and ribavirin] and [sofosbuvir, daclatsvir and ribavirin] on patients above and below the age of 60 years

ABSTRACT

Background: the goal of antiviral treatment is to prevent complications of the disease, mainly cirrhosis and HCC. New therapy options, known as direct acting antiviral [DAA] regimens, offer the promise of increased success rates complimented by shorter treatment durations, improve side effect profiles, and simplified treatment monitoring